ofloxacin has been researched along with Joint Diseases in 14 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Joint Diseases: Diseases involving the JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens." | 1.62 | Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study. ( Arvieux, C; Bellissant, E; Comets, E; Fily, F; Foulquier, JB; Huten, D; Jullien, V; Laviolle, B; Lemaitre, F; Petitcollin, A; Polard, JL; Revest, M; Tattevin, P; Tron, C; Verdier, MC, 2021) |
| "Ozenoxacin is a nonfluorinated quinolone antibacterial approved for topical treatment of impetigo." | 1.48 | Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs. ( Awori, MS; Blazquez, T; Chouinard, L; Gargallo-Viola, D; González Borroto, JI; Smith, SY; Tarragó, C; Zsolt, I, 2018) |
| "5 and 6 h after dosing and the drug was still detectable in plasma 48 h after dosing (0." | 1.30 | Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. ( Förster, C; Günther, T; Lozo, E; Merker, HJ; Schwabe, R; Stahlmann, R; Vormann, J; Zippel, U, 1997) |
| "Ofloxacin was orally administered to these dogs at 20 mg/kg once daily for 8 consecutive days, and the animals were killed 2 h after the last treatment." | 1.30 | Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. ( Furuhama, K; Nishida, S; Ohshima, C; Sekiguchi, M; Yabe, K; Yamada, K; Yamamoto, N; Yoshida, K, 1998) |
| "2." | 1.30 | The comparative arthropathy of fluoroquinolones in dogs. ( Hashimoto, K; Minami, T; Owen, K; Takizawa, T; Yamashita, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (50.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Lemaitre, F | 1 |
| Fily, F | 1 |
| Foulquier, JB | 1 |
| Revest, M | 1 |
| Jullien, V | 1 |
| Petitcollin, A | 1 |
| Tattevin, P | 1 |
| Tron, C | 1 |
| Polard, JL | 1 |
| Verdier, MC | 1 |
| Comets, E | 1 |
| Huten, D | 1 |
| Arvieux, C | 1 |
| Bellissant, E | 1 |
| Laviolle, B | 1 |
| González Borroto, JI | 1 |
| Awori, MS | 1 |
| Chouinard, L | 1 |
| Smith, SY | 1 |
| Tarragó, C | 1 |
| Blazquez, T | 1 |
| Gargallo-Viola, D | 1 |
| Zsolt, I | 1 |
| El Samad, Y | 1 |
| Havet, E | 1 |
| Bentayeb, H | 1 |
| Olory, B | 1 |
| Canarelli, B | 1 |
| Lardanchet, JF | 1 |
| Douadi, Y | 1 |
| Rousseau, F | 1 |
| Lescure, FX | 1 |
| Mertl, P | 1 |
| Eb, F | 1 |
| Schmit, JL | 1 |
| Postnikov, SS | 1 |
| Semykin, SIu | 1 |
| Nazhimov, VP | 1 |
| Novichkova, GA | 1 |
| Yabe, K | 2 |
| Satoh, H | 1 |
| Ishii, Y | 1 |
| Jindo, T | 1 |
| Sugawara, T | 1 |
| Furuhama, K | 2 |
| Goryo, M | 1 |
| Okada, K | 1 |
| Legout, L | 1 |
| Senneville, E | 1 |
| Stern, R | 1 |
| Yazdanpanah, Y | 1 |
| Savage, C | 1 |
| Roussel-Delvalez, M | 1 |
| Rosele, B | 1 |
| Migaud, H | 1 |
| Mouton, Y | 1 |
| Bindal, M | 1 |
| Krabak, B | 1 |
| Förster, C | 1 |
| Schwabe, R | 1 |
| Lozo, E | 1 |
| Zippel, U | 1 |
| Vormann, J | 1 |
| Günther, T | 1 |
| Merker, HJ | 2 |
| Stahlmann, R | 2 |
| Yoshida, K | 1 |
| Nishida, S | 1 |
| Yamamoto, N | 1 |
| Ohshima, C | 1 |
| Sekiguchi, M | 1 |
| Yamada, K | 1 |
| Arora, VK | 1 |
| Tumbanatham, A | 1 |
| Takizawa, T | 1 |
| Hashimoto, K | 1 |
| Minami, T | 1 |
| Yamashita, S | 1 |
| Owen, K | 1 |
| Taşova, Y | 1 |
| Saltoğlu, N | 1 |
| Sahin, G | 1 |
| Aksu, HS | 1 |
| Reynaud, AE | 1 |
| Espaze, EP | 1 |
| Coste-Burel, M | 1 |
| Richet, H | 1 |
| Hinz, N | 1 |
| Chahoud, I | 1 |
| Webb, J | 1 |
| Heger, W | 1 |
| Neubert, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model[NCT02357407] | Phase 4 | 31 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ofloxacin and Joint Diseases
| Article | Year |
|---|---|
[On fluoroquinolones treatment safety in children (clinical, morphological and catamnesis data)].
Topics: Adolescent; Age Factors; Anemia, Aplastic; Anti-Infective Agents; Body Height; Cartilage; Child; Chi | 2002 |
13 other studies available for ofloxacin and Joint Diseases
| Article | Year |
|---|---|
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases, Infectious; Female; Fluoroquin | 2021 |
Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs.
Topics: Administration, Oral; Aminopyridines; Animals; Anti-Bacterial Agents; Biomarkers; Cartilage, Articul | 2018 |
[Treatment of osteoarticular infections with clindamycin in adults].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases; Clindamy | 2008 |
Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobial agent.
Topics: Age Factors; Animals; Anti-Bacterial Agents; Cartilage, Articular; Cells, Cultured; Chondrocytes; Do | 2004 |
Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases, Infectious; Cefepime; Cephalos | 2006 |
Acute bacterial sacroiliitis in an adult: a case report and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Clindamycin; Female; Humans; Joint Diseases; Low | 2007 |
Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics.
Topics: Age Factors; Animals; Anti-Infective Agents; Calcium; Cartilage; Ciprofloxacin; Contraindications; F | 1997 |
Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs.
Topics: Administration, Oral; Age Factors; Animals; Anti-Infective Agents; Area Under Curve; Cartilage, Arti | 1998 |
Severe arthropathy with ofloxacin in two cases of MDR tuberculosis.
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Female; Humans; Joint Diseases; Ofloxacin; Tube | 1998 |
The comparative arthropathy of fluoroquinolones in dogs.
Topics: Animals; Anti-Infective Agents; Body Weight; Ciprofloxacin; Dogs; Eating; Fluoroquinolones; Joint Di | 1999 |
Osteoarthricular involvement of brucellosis in Turkey.
Topics: Adolescent; Adult; Age Distribution; Aged; Brucella; Brucellosis; Doxycycline; Female; Humans; Joint | 1999 |
[In vitro kinetics of the activity of fusidic acid and fluoroquinolones combinations against staphylococci according to methicillin-resistance phenotype. Implications for the treatment of osteoarticular infections].
Topics: Bone Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fusidic Acid; Humans; In | 1992 |
Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations.
Topics: Administration, Oral; Animals; Callitrichinae; Joint Diseases; Knee Joint; Male; Microscopy, Electro | 1990 |